ARCHIVES

Ibrutinib Demonstrates 71% ORR In Phase Ib/II CLL and SLL Study

This article is from The Cancer Letter archive.

Vol. 36 No. 7 | July 26, 2013

Download PDF Visit The Full Archive

Related Articles

In Brief: Lee Helman To Head NCI Pediatric Branch; HHS to Hear From Academic Health Centers

August 22, 1997

Is More Better? ASCO Plenary Session Opens Debate On High-Dose Chemotherapy

May 28, 1999

ASCO Honors Community Practices For Trial Participation.

June 1, 2007

NCI Clamps Down On Site Visits, Announces New Policy To Reduce Number, Improve Quality

April 26, 1974

Breast Cancer action Plan Calls For More federal Coordination, Patient Participation

March 23, 1994

Clinical Trials Approved By NCI In November

December 28, 2001